Drug–Drug Interactions—New Perspectives

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 30 October 2025 | Viewed by 45

Special Issue Editors


E-Mail Website
Guest Editor
Department of Physical Pharmacy and Pharmacokinetics, Poznań University of Medical Sciences, 60-781 Poznan, Poland
Interests: drug analysis; pharmacokinetics; aritficial neural networks; data mining; drug–drug interactions
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Physical Pharmacy and Pharmacokinetics, Poznań University of Medical Sciences, Poznan, Poland
Interests: therapeutic drug monitoring; HPLC; method validation; polymorphism; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Physical Pharmacy and Pharmacokinetics, Poznań University of Medical Sciences, Poznan, Poland
Interests: therapeutic drug monitoring; pediatrics; analytical methods; population pharmacokinetics; drug–drug interactions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug–drug interactions (DDI) represent a significant challenge in healthcare, arising when two or more substances, including pharmaceuticals and dietary supplements, interact with one another. These interactions can profoundly affect the pharmacokinetics and pharmacodynamics of the involved drugs, potentially diminishing therapeutic efficacy and increasing the risk of adverse effects.

This Special Issue invites research that examines DDIs, particularly those resulting from co-medication. We are particularly interested in studies that investigate the pharmacokinetic profiles altered by these interactions, as well as the resultant impacts on drug metabolism, distribution, and excretion. Manuscripts discussing side effects that emerge from medical procedures are also encouraged.

Research focusing on specific patient populations, especially pediatric and elderly patients, is of prime interest due to their distinct pharmacokinetic characteristics that may heighten vulnerability to DDIs.

We encourage the application of advanced analytical methods, including statistical modeling and machine learning techniques, for evaluating DDIs. However, submissions employing these models must include supporting biological experiments to confirm findings and ensure their relevance within the scope of pharmaceutics and pharmacokinetics.

Dr. Andrzej Czyrski
Dr. Matylda Resztak
Dr. Joanna Sobiak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • safety of therapy
  • cytochrome P450
  • pharmacokinetics
  • contraindication
  • machine learning
  • metabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop